Decoding pH‐Driven Phase Transition of Lipid Nanoparticles

Why It Matters

Understanding the environment‑driven pKa shift enables rational engineering of LNPs for higher delivery efficiency and lower therapeutic doses, a critical advantage for mRNA vaccine and drug platforms.

Key Takeaways

• Intrinsic aminolipid pKa drops four units in LNPs.
• ALC‑0315 pKa shifts from 9.3 to 4.9 inside LNP.
• Surface protonation drives mRNA encapsulation at low pH.
• Core deprotonation stabilizes LNP structure near neutral pH.
• Localized pKa varies from ~8 at surface to ≤4 core.

Pulse Analysis

Lipid nanoparticles have become the backbone of modern mRNA vaccines, with ionizable aminolipids acting as the molecular switches that control cargo release. The protonation state of these lipids determines how the particle interacts with cellular membranes and how efficiently it can protect and deliver its genetic payload. While the intrinsic pKa of aminolipids is well‑characterized in aqueous solution, the crowded, heterogeneous environment inside an LNP can dramatically alter this value, influencing both stability and transfection performance.

Using large‑scale constant‑pH molecular dynamics, researchers mapped the pKa landscape of the Comirnaty formulation’s key aminolipid, ALC‑0315. The simulations revealed an apparent pKa of 4.9 within the nanoparticle, a shift of more than four units from the water‑phase intrinsic pKa of 9.3. This downward shift stems from lipid reorganization and strong electrostatic screening, creating distinct protonation zones: the outer surface remains protonated at acidic pH, while deeper regions become deprotonated as pH rises. The localized pKa gradient ranges from ~8 near the surface to ≤4 in the core.

These insights provide a mechanistic basis for the pH‑triggered phase transition that underlies LNP fusion and endosomal escape, offering a blueprint for next‑generation carrier design. By engineering aminolipids with tailored pKa profiles, formulators can fine‑tune particle disassembly, improve mRNA release, and reduce dose requirements. The study bridges computational predictions with experimental observations, reinforcing the role of molecular‑level modeling in accelerating vaccine development and broader nanomedicine applications.